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Abstract: Elastin-like peptide (ELP) was fused to two different avian flu H5N1 antigens 
and expressed in transgenic tobacco plants. The presence of the ELP tag enhanced the 
accumulation  of  the  heterologous  proteins  in  the  tobacco  leaves.  An  effective  
membrane-based  Inverse  Transition  Cycling  was  developed  to  recover  the  ELPylated 
antigens  and  antibodies  from  plant  material.  The  functionality  of  both  the  ELPylated 
neuraminidase and an ELPylated nanobody was demonstrated. 
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1. Introduction 
The use of transgenic plants to synthesize antigens and antibodies was first reported over 20 years 
ago [1,2], and since this time, various methods have been developed to generate both plant-based 
vaccines  and  plantibodies  (for  review  see  [3–7]).  Using  plants  to  make  these  molecules,  offers 
significant advantages over mammalian cell-based systems in scale, economy and product safety, as 
well as providing  a simple means of storage and distribution in the form of the seed (for review  
see [4,8]). Target extraction, recovery and purification, which normally involves chromatography and 
its associated labor and capital equipment, represents over 80% of the overall production cost [9]. 
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These  costs  are  independent  of  the  primary  production  system,  but  in  planta  systems  are  less 
demanding than in vitro ones with respect to the upstream components, as they avoid the need for 
fermentation equipment and culture media [8]. As a result, the per gram cost of therapeutic proteins 
produced by mammalian cells is substantially higher than that from plants [10]. The major technical 
bottleneck associated with in planta production lies in the down-stream processing procedure [11]. 
Here the major challenges concern firstly the removal of contaminating proteins (especially proteases), 
carbohydrates,  oils,  phenolic  compounds,  phytic  acid,  nucleic  acid  and  other  trace  products,  and 
secondly the low concentration of the target in the initial aqueous extraction [12]. Thus, successful 
purification  depends  heavily  on  inducing  a  high  concentration  of  the  target  molecule  in  the  
plant material.  
The  fusion  of  transgenic  proteins  to  elastin-like  peptides  (ELPs)  is  known  to  enhance  the 
accumulation of transgenic proteins in planta (for review see [13,14]), and ELPylated proteins are 
known  to  induce  immune  responses  [15].  ELPylation  has  the  further  benefit  of  simplifying  the 
subsequent  purification  via  Inverse  Transition  Cycling  (ITC),  a  method  based  on  the  inherent 
reversibility of ELPylation (for review see [13]). This approach has been successfully demonstrated for 
the  expression  and  purification  of  vaccines  [15],  complete  immunoglobulins  [16,17],  antibody 
fragments [18,19] and several other proteins (for review see [13,14]). The centrifugation-based ITC 
method (cITC) relies on the precipitation of ELPylated proteins by a combination of salting, heating, 
centrifugation and resolubilization in the absence of salt at a lower temperature [20], a method which 
has been further improved by the use of microfiltration to isolate the precipitate [21]. Recently, we 
have shown that an in planta produced ELPylated cameloid-based nanobody against hTNFα can be 
purified by cITC and size exclusion chromatography, and that this molecule was able to neutralize the 
cytotoxic  effect  of  hTNFα  in  human  cells  and  prevent  sepsis  in  a  mouse  model.  The  ELPylated 
nanobody showed a significant enhancement of half-life [19]. 
Avian flu has grown in importance as a disease affecting both domestic animals and humans (for 
review see [22,23]). A full-length hemagglutinin which induces the production of virus-neutralizing 
antibodies in mice has been produced in planta [24,25], and the same hemagglutinin has been shown 
to  protect  ferrets  against  the  virus  [26,27].  Similarly,  plant-produced  hemagglutinin  vaccines  are 
effective in chickens in a challenge study [28]. Plant-produced transgenic antigens have been purified 
from  the  plant  matrix  using  either  Protein  A  based  affinity  chromatography  via  Fc  fusions  [29],  
Ni-column chromatography and anion exchange chromatography [27], or a combination of two phase 
separations,  several  membrane  filtration  steps  and  gel  filtration  [28].  Here  we  demonstrate  the 
purification  of  both  ELPylated  avian  flu  hemagglutinin  and  neuraminidase  (NA)  synthesized  in 
transgenic tobacco plants using a membrane-based ITC (mITC) method.  
2. Results and Discussion 
2.1. Generation of Transgenic Tobacco Plants Expressing Hemagglutinin and NA Sequences  
The avian flu antigens neuraminidase and hemagglutinin are important targets for the production of 
neutralizing  antibodies  [24,30,31],  (for  review  see  [32]).  Expression  cassettes  were  designed  to 
synthesize  hemagglutinin  H5  (HA1  (A/Hatay/2004/(H5N1),  GenBank  Q5QQ29)  and  NA  N1 Int. J. Mol. Sci. 2011, 12                       
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((A/Hatay/2004/(HHN1), GenBank Q5QQ28) in planta. The transgenic protein was targeted to the 
endoplasmic reticulum by ER retention, as this ensures high and stable accumulation [33], (for review 
see  [34]).  ELPylated  versions  of  both  antigens  were  also  included  to  both  enhance  the  level  of  
in planta expression and to permit purification via ITC (Figure 1a, for review see [13]). Transgenic 
plants were produced with all four constructs using Agrobacterium-mediated transformation (Table 1). 
Whereas  the  in  planta  expression  of  hemagglutinin  (H5)  has  already  been  achieved  
elsewhere [24,28,29], we believe that this is the first report of in planta synthesis of NA N1. 
ELPylation enhanced the expression of both NA and hemagglutinin, as it has been documented to 
achieve for a range of other transgenic proteins including antigens and antibodies [16–19,35,36]. The 
extent of the enhancement appears to depend on the number of ELP repeats included in the expression 
cassette [36], and here, the use of 100 repeats produced a high level of expression of both antigens 
(Table 1, Figure 1).  
Figure  1.  The  heterologous  expression  of 
NtN1  and 
NtHA1  in  tobacco.  (a)  Schematic 
representation of the expression cassettes. The N1 and HA1 subunit encoding sequences 
were cloned in frame with a legumin signal peptide (SP), a his tag, a c-myc-tag, the ER 
retention signal (KDEL) and either with or without 100 repeats of the ELP pentapeptide 
VPGXG. N1: NA; HA1: HA1 subunit 1 of hemagglutinin subtype 5; (b) 
NtN1-ELP and 
NtN1  protein,  as  detected  by  Western  blotting  using,  respectively,  2.5  and  25  µg  total 
soluble protein (TSP); (c) 
NtHA1-ELP and 
NtHA1, as detected by Western blotting using, 
respectively, 2.0 and 30 µg TSP. The numbers refer to independent primary transgenic 
plants. Wt: wild type tobacco; C+: 1ng 
Ntanti-hTNFα-VHH-ELP used as a Western blot 
standard. Arrows indicate the target recombinant proteins. 
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Figure 1. Cont. 
NtN1-ELP              NtN1       
C+   15     29     32       8     23    33    Wt
130
95
72
55
k
D
a
43
NtN1-ELP
NtN1
(b)
NtN1-ELP              NtN1       
C+   15     29     32       8     23    33    Wt
130
95
72
55
k
D
a
43
NtN1-ELP
NtN1
(b)
 
 
170
130
95
72
55
k
D
a
43
34
NtHA1-ELP              NtHA1       
4       8     14      8      9      10   Wt     C+ 
NtHA1-ELP
NtHA1
(c)
170
130
95
72
55
k
D
a
43
34
NtHA1-ELP              NtHA1       
4       8     14      8      9      10   Wt     C+ 
NtHA1-ELP
NtHA1
(c)
 
Table  1.  Transgenic  tobacco  plants  expressing  neuraminidase  N1,  hemagglutinin 
(H5, HA1) or the respective ELPylated fusion proteins.  
Transgene 
Number of 
Regenerated 
Plants 
Number of 
Transgene 
Expressing Plants 
Transgene 
Expression (%TSP) 
 
NtN1  42  23  0.004% 
NtN1-ELP  37  23  0.2% 
NtHA1  36  22  0.01% 
NtHA1-ELP  88  67  0.3% 
Transgenic proteins were detected by Western blot. 
2.2. Purification of 
NtHA1-ELP, 
NtN1-Elp Using Centrifugation-Based ITC (cITC) 
Both antigens were readily purified by cITC. The NA antigen was accompanied by other plant 
proteins (Figures 2a, 4a), resulting in a purification efficiency of 40.0% (in terms of protein amount) 
and 33.7% (in terms of enzymatic activity) (Table 2). For the hemagglutinin antigen, the method 
resulted  in  the  near  complete  disappearance  of  the  full-length  hemagglutinin-ELP  fusion;  what 
remained was one cleavage product consisting of the ELP repeats and the cmyc-tag (Figure 2b). The 
recovery efficiency of this protein was high (Table 2). In general, the recovery efficiency of cITC was 
in accordance with the literature [19,36]. Int. J. Mol. Sci. 2011, 12                       
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Figure  2.  cITC  purification,  as  demonstrated  by  Western  blot  analysis.  (a) 
NtN1-ELP;  
(b) 
NtHA1-ELP. RE: raw extract; Sc: Supernatant after heat centrifugation; Pc: Proteins 
captured in the pellet after heat centrifugation and solubilization in water. Arrows indicate 
the target recombinant proteins. 
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Table  2.  Efficiency  of  purification  of  various  recombinant  target  proteins  by  mITC  
and cITC. 
Recombinant proteins 
Recovery (%) 
mITC  cITC 
NtHA1-ELP  95*  98* 
NtN1-ELP  92.5**–94*  33.7**–40* 
Ntanti-hTNFα-VHH-ELP  98*  11* [19] 
Determined by *amount (Western blot) or **activity. 
2.3. Purification Using Membrane-Based ITC (mITC) 
To overcome the proteolytic cleavage and/or partial denaturation of the ELPylated protein which 
affected the cITC purification (probably caused by a higher than optimal temperature regime), we 
adapted the filter-based ITC method described by Ge et al. [21]. For each of the three transgenic 
products  (
NtHA1-ELP, 
NtN1-ELP  and 
Ntanti-hTNFα-VHH-ELP),  the  expected  size  molecule  was 
successfully purified (Figure 3). Losses due to filtration at room temperature and the presence of 2 M 
NaCl  were  either  insignificant  (Figure  3a,b)  or,  at  worst,  minimal  (Figure  3c).  Since  the  
re-solubilization rate was very high, the mITC purification efficiency was excellent (Table 2). For NA 
in particular, the procedure led to a large improvement in the degree of purity achieved (Figure 4a). 
For hemagglutinin, some proteolytic cleavage still occurred, but most of the product remained intact 
(Figure 4b). The robustness of the mITC method was proven by repeating the procedure four times for 
each target (Figure 5). Int. J. Mol. Sci. 2011, 12                       
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Figure  3. mITC purification, as demonstrated by Western blot analysis. (a) 
NtN1-ELP;  
(b) 
NtHA1-ELP;  (c) 
Ntanti-hTNFα-VHH-ELP.  RE:  Raw  extract;  Sm:  Supernatant  raw 
extract  passed  through  a  0.2  µm   cellulose  acetate  membrane  at  room  temperature;  
Pm:  Proteins  eluted  from  the  membrane  by  ice-cold  water.  Arrows  indicate  the  target 
recombinant proteins. 
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Figure  4.  In  gel  staining  (Coomassie  Blue)  analysis  of  purification.  (a) 
NtN1-ELP;  
(b)
 NtHA1-ELP. Pm: proteins eluted from the membrane by water; Pc: proteins captured in 
the pellet after heat centrifugation and solubilization in water. Arrows indicate the target 
recombinant proteins. 
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Figure  5.  Robustness  of  the  mITC  purification.  (a) 
NtN1-ELP;  (b) 
NtHA1-ELP;  
(c) 
Ntanti-hTNFα-VHH-ELP. Pm1-Pm4 refer to the four replicated purifications. 
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Purification procedures need to be optimized not only with respect to their recovery efficiency, but 
also to maintain biological activity. The three ELPylated proteins expressed in planta and purified by 
mITC were highly soluble even at relatively high concentrations. The enzymatic activity of the NA, 
assessed on the basis of its ability to cleave 2’-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid, 
was over four fold that of the cITC purified equivalent (Table 3). The binding behavior of the mITC 
purified nanobody 
Ntanti-hTNFα-VHH-ELP was investigated by a competitive ELISA, in which it 
exhibited  a  dissociation  constant  of  ~4.5  nM  (Figure  6),  comparable  to  the  behavior  of  its  cITC 
purified equivalent (4 nM, [19]).  
We have demonstrated here that a refinement of the mITC method permits a rapid, inexpensive and 
efficient means of purifying in planta expressed ELPylated transgenic proteins. The purified products 
showed a high degree of integrity, were highly soluble and exhibited excellent biological activity in 
terms of their binding or their enzymatic cleavage. Further developments will concentrate on a scaling 
up of the procedure to verify that this technology is able to circumvent the major bottleneck affecting 
the in planta production of antigens and antibodies [11].  
Table 3. Enzymatic activity of 
NtN1-ELP. 
The 
NtN1-ELP activity was determined by fluorescence assay before and after purification by mITC 
or cITC. Data were calculated for 1 kg of leaf material.  
 
Status of 
NtN1-ELP  Total protein 
(mg) 
Total activity 
(U) 
Recovery rate 
(%) 
Specific activity  
(U mg
−1) 
Raw extract  3521.9  736.5  100  0.21 
Purified 
NtN1-ELP by mITC  20.3  681.1  92.5  33.6 
Purified 
NtN1-ELP by cITC  31.2  248.5  33.7  7.96 Int. J. Mol. Sci. 2011, 12                       
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Figure 6. The binding behavior of 
Ntanti-hTNFα-VHH-ELP to human TNFα, as assessed 
by competitive ELISA. 
Ntanti-hTNFα-VHH-ELP was mixed with various concentrations of 
hTNFα. The solid phase binding of c-myc tagged 
Ntanti-hTNFα-VHH-ELP to hTNFα was 
quantified.  Binding  without  competition  from  free  hTNFα  was  set  to  100%.  Standard 
deviations shown as bars. 
 
3. Experimental Section 
3.1. Plant Transformation Vectors 
The hemagglutinin (HA) sequence encoding amino acids 2–568 of the A/Hatay/2004/(H5N1) strain 
of the avian flu virus was optimized for expression in tobacco plants and synthesized by GENEART 
AG  (Regensburg,  Germany).  This  sequence  was  designated  pPCRScript-opHA0.  Truncated 
hemagglutinin  HA1  and  NA  N1  sequences  were  obtained  by  a  two-step  cloning  strategy.  First,  
a polyhistidine afﬁnity puriﬁcation tag (6xHis) was added to the C-terminus of TBAG to create the 
vectors  pRTRA-TBAG  and  pRTRA-TBAG-ELP  [15]  comprising  the  constitutively  expressing 
cauliﬂower mosaic virus (CaMV) 35S promoter, the legumin B4 (LeB4) signal peptide (SP), TBAG,  
a c-myc tag, respectively 0 and 100 copies of ELP, and the KDEL ER retention signal. Next, the DNA 
sequence encoding A/Hatay/2004/(H5N1) HA1 (amino acids 17–342) and NA1 (amino acids 38–449) 
were  PCR  amplified  using,  respectively  pPCRscript-opHA0  and  pPCR-N1  (GenBank  accession 
AJ867075) as template; the amplicon was inserted into pRTRA-TBAG and pRTRA-TBAG-ELP to 
replace the sequence DNA encoding TBAG to form the four expression cassettes pRTRA-35S-HA1,  
pRTRA-35S-HA1-ELP,  pRTRA-35S-N1  and  pRTRA-35S-N1-ELP  (Figure  1a).  Each  cassette  was 
then HindIII digested and inserted into the pCB301-based shuttle vector pCB301-Kan [16,37].  
3.2. Plant Transformation 
The  pCB301-Kan  vectors  were  electroporated  into  Agrobacterium  tumefaciens  strain  C58C1 
(pGV2260)[38]  which  was  then  used  to  transform  the  tobacco  cultivar  SNN  via  a  leaf  disk  
nM hTNFα 
KD = 4.5 nM 
% Binding Int. J. Mol. Sci. 2011, 12                       
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method [39]. Transgenic plants were cultured on Murashige and Skoog medium containing 50 mg/L 
kanamycin  and  analyzed  by  Western  blot  using  a  monoclonal  antibody  anti-c-myc  antibody. 
Transgenic high-producer tobacco lines were selected and further propagated. 
3.3. ITC Purification of ELP Fusion Proteins  
Frozen leaf (150 g) was ground with mortar and pestle in liquid nitrogen and homogenized in  
220 mL ice-cold 50 mM Tris-HCl (pH 8.0). A Complete Protease Inhibitor Cocktail tablet (Roche, 
Germany) was added to the slurry, which was then cleared by centrifugation (75,600 g, 30 min, 4 ° C) 
before the addition of NaCl to a final concentration of 2 M. The cold extract with 2 M NaCl was 
centrifuged again at 75,600 g for 30 min at 4 °C . The solution was then passed through a 0.22 µm 
polyethersulfone membrane (Corning, USA) with the temperature maintained at 4 ° C, to produce a 
pre-treated extract. For the cITC, the pre-treated extract was first incubated for 30 min at 40 °C  (for 
NtN1-ELP  purification)  or  55  °C   (
NtHA1-ELP)  to  induce  aggregation  of  the  antigen-ELP  fusions, 
which were then precipitated by centrifugation (8000 g, 30 min, 40 °C  or 55 ° C, respectively). The 
resulting pellet was dissolved in water at 4 ° C, and any insoluble matter removed by centrifugation 
(15,000 g, 30 min, 4 ° C). For the mITC, the pre-treated extract was warmed to room temperature, and 
passed through a 0.2 µm  cellulose acetate membrane (Sartorius Stedim, Goettingen, Germany) using a 
vacuum pump (Vacuubrand, Germany). The membrane was washed twice with 2 M NaCl to remove 
contaminating proteins. Ice-cold Millipore-Q water was then passed through the filter to elude the 
protein-ELP fusions.  
3.4. SDS-PAGE and Western Blotting 
Frozen leaf discs were homogenized in a Mixer Mill MM 300 (Retsch, Haan, Germany) and the 
resulting powder suspended in SDS sample buffer (72 mM Tris, 10% v/v glycerine, 3% w/v SDS,  
5% v/v β-mercapethanol, 0.25 µM bromophenol blue, pH 6.8), held at 95 °C  for 10 min and then 
centrifuged (19,000 g, 30 min, 4 ° C). The concentration of total soluble protein (TSP) present was 
determined  using  the  Bradford  assay  (Bio-Rad,  Munich,  Germany).  Extracted  plant  proteins  were 
separated  by  reducing  SDS-PAGE  (10%  polyacrylamide)  and  electrotransferred  to  nitrocellulose 
membranes. After blocking with 5% w/v fat-free milk powder dissolved in TBS (20 mM Tris, 180 mM 
NaCl,  pH  7.8),  the  membranes  were  incubated  for  2  h  at  room  temperature  with  a  monoclonal  
anti-c-myc antibody. The presence of this antibody was detected by the addition of a 1:2000 dilution of 
HRP-conjugated sheep anti-mouse IgG (Amersham, Germany), and the signal visualized using the 
ECL method (Amersham Biosciences). Each membrane was washed three times between each step 
with  TBS  containing  0.5%  w/v  fat-free  milk,  except  for  the  penultimate  (TBS  only)  and  final 
(phosphate-buffered  saline,  PBS)  washes.  Antibodies  were  diluted  in  TBS,  5%  w/v  fat-free  
milk powder.  
3.5. Determination of Purification Efficiency 
The  purification  efficiency  of  the  various  recombinant  protein-ELP  fusions  was  assessed  by 
sampling the plant extract both before and after the cellulose acetate filtration (mITC method), or Int. J. Mol. Sci. 2011, 12                       
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before and after the hot centrifugation (cITC method). The samples were serially diluted to allow a 
semi-quantitative  Western  blotting-based  analysis  (as  described  in  3.4).  Band  intensities  were 
compared by image densitometry, using totalLab TL100 software (Nonlinear Dynamics, USA).  
3.6. 
NtN1-ELP Activity Assay 
A fluorescence-based assay was used to measure NA activity, as described elsewhere [40,41]. The 
assay was formed by adding a 10 µL aliquot of the 
NtN1-ELP sample to an equal volume of 32.5 mM 
MES, 4 mM CaCl2, pH 6.5. The enzymatic reaction was then initiated by the addition of 30 µL  
2’-(4-methylumbelliferyl)-α-D-N-acetylneuraminic  acid  (Sigma,  St.  Louis,  MO,  USA).  After 
incubation at 37 °C  for 30 min, the reaction was stopped by the addition of 150 µL 100 µM glycine  
(pH  10.7)  in  25%  ethanol.  The  release  of  4-methylumbelliferone  (4-MU)  was  measured 
spectrophotometrically at 355 and 460 nm, and quantification was based on a standard curve prepared 
with pure free 4-MU (Sigma, St. Louis, MO, USA). One unit of NA was defined as the quantity able to 
release 1 µM 4-MU per min at 37 ° C. To determine the efficiency of 
NtN1-ELP purification based on 
its NA activity, total protein was precipitated from the initial plant extract with ammonium sulfate, and 
pelleted by centrifugation (38,000 g, 30 min, 4 °C ). The pellet was re-solubilized in PBS, and the 
sample treated as above to determine NA activity. The % recovery of 
NtN1-ELP based on NA activity 
was defined as the ratio between the NA activity before and after purification.  
3.7. Competitive ELISA 
Microtitre  plates  (ImmunoPlate  Maxisorp,  Nalge  Nunc  International,  Roskilde,  Denmark)  were 
coated with 1 µg/mL recombinant human TNFα in PBS and incubated overnight at room temperature. 
After blocking with 3% w/v bovine serum albumin (BSA), 0.05% v/v Tween20 in PBS (PBST) for 
2 h,  pre-determined  quantities  of 
Ntanti-hTNFα-VHH-ELP  mixed  with  various  concentrations  of 
hTNFα in 1% w/v BSA in PBST were added to each well, and the plates incubated for 1.5 h at 25 °C .  
Bound 
Ntanti-hTNFα-VHH-ELP  was  visualized  by  treatment  with  anti-c-myc  antibody  and  rabbit  
anti-mouse IgG alkaline phosphatase conjugate (SIGMA-Aldrich, St. Louis, MO, USA) diluted in 1% 
w/v BSA in PBST. The enzymatic substrate was pNP phosphate, and the absorbance was measured 
after  a 60 min incubation at 37 °C . Five replicates were measured for each concentration of  free 
hTNFα used for competition. 
4. Conclusions 
Avian  flu  virus  H5N1  hemagglutinin  (H5)  and  neuraminidase  (NA,  N1)  have  been  expressed 
transgenically  in  tobacco.  The  level  of  heterologous  expression  was  greatly  enhanced  by  fusing  
100 ELP repeats to the C-terminus of each protein. The enhanced expression of the two main targets 
for neutralizing antibodies of the Avian flu virus in transgenic tobacco allows the development of 
combined vaccination strategies with both antigens.  
Refinements  to  the  mITC  method  produced  an  efficient,  rapid  and  non-expensive  means  of 
purifying the in planta synthesized ELPylated proteins. The critical improvements to the purification 
protocol were the clearance of the initial extract, a second clearance step after addition of NaCl to 2 M Int. J. Mol. Sci. 2011, 12                       
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in the cold, a rapid and efficient precipitation reaction, and the elution of the target from the membrane 
with ice-cold water. The integrity of the resulting products was high, and they also showed a good 
level of biological activity. Immunization experiments will be required to show that in planta produced 
ELPylated hemagglutinin and neuraminidase can provide effective protection against infection. 
The recovery efficiency of the membrane-based ITC procedure was very high in all three examples. 
This  is  essentially  true  for  the  purification  of 
Ntanti-hTNFα-VHH-ELP.  Active  nanobody  with 
comparable affinities has been produced by centrifugation-based ITC, too, but with a ten times lower 
recovery efficiency (Table 2). The mITC method described in this paper could also be adapted in 
future to the purification of ELPylated complete antibodies, suitable for therapeutic purposed [16,17]. 
In  general  we  conclude  that  ELPylation  is  an  appropriate  strategy  for  the  development  of  
plant-based vaccines and plantibodies. Scaling up experiments will now be necessary to confirm that 
this purification approach will be able to circumvent the major bottleneck which at present inhibits the 
in planta production of antigens and antibodies, i.e., the down-stream costs [11].  
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